TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07436611: Rapamycin Dose-Ranging Efficacy Study in Port Wine Stains

Sponsor: AFT Pharmaceuticals, Ltd. · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 30 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$398,400

Rescue Site Savings

+$265,600

Unlock Full NCT07436611 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07436611 Rescue Dossier →